06 November 2023 | News
New agreement will focus on a specific type of cancer
Image credit: shutterstock
XtalPi, a leading global technology company in combining artificial intelligence (AI) and robotics to drive the discovery of groundbreaking medicine and innovative materials, has announced the signing of a new agreement with CK Life Sciences, a member of the CK Hutchison Group.
Expanding upon their existing partnership, the two companies will combine AI algorithms with anonymised clinical and biomarker data from cancer patients and healthy individuals in CK Life Sciences' data repository to jointly explore and develop miRNA-based postoperative molecular diagnostic models for prognostic risk prediction.
With the help of AI and machine learning models, this collaborative engagement will hopefully lead to the development of more advanced and intelligent solutions for the processing and modeling of holistic multidimensional biomedical data, biomarker discovery, and postoperative recurrence risk prediction.
The primary objective of this project is to develop groundbreaking modeling capabilities for miRNA data. By doing so, XtalPi and CK Life Sciences aim to create clinically applicable, high-precision tumor diagnostic tools that can enhance physicians' ability to reliably assess postoperative cancer recurrence risks among patients and implement better-tailored treatment plans to improve patient survival rates and quality of life.
Concurrently, the two companies will endeavor to identify crucial biomarkers and develop robust computational models for clinical diagnosis, disease management, and the discovery of novel therapeutics. The models and methods derived from this project will lay the foundation for future collaborations involving larger and more complex datasets.